^
Association details:
| Biomarker: | RET-MIR4299-MIR8070 fusion + RET amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
Published date:
09/26/2022
Excerpt:
In this case, a 60-year-old man was diagnosed with advanced lung adenocarcinoma. A novel RET-MIR4299/MIR8070 fusion and RET amplification were identified using next-generation sequencing (NGS). The patient was then administered with pralsetinib. After 3 weeks of therapy, the patient had a partial response. At the time of reporting, the patient was on continuous pralsetinib.
DOI:
10.3389/fonc.2022.929763
